novo nordisk weight loss - Search News

Novo Nordisk, Obesity Drug

Novo Nordisk next-gen shot shows 22% weight loss in early results

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.

Hosted on MSN · 1d

Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results

KEY TAKEAWAYS Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.The maker of Ozempic and Wegovy said that its Phase 1b/2a trial showed people achieved weight loss from a mean baseline body weight of 92.

The Wall Street Journal on MSN · 1d

Novo Nordisk Shares Surge on New Obesity Drug Results

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients lost 22% of their bodyweight in a clinical trial.

1don MSN

The Score: Novo Nordisk, Oracle, Netflix, and More Stocks That Defined the Week

Here are some of the major companies whose stocks moved on the week’s news.

5don MSN

LVMH dethrones Novo Nordisk as Europe’s most valuable company as Bernard Arnault adds $12 billion to net worth in 2025

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results